Baxter International Inc.

Baxter Healthcare Sa

Other

British Technology Group Limited

Aventis Behring Gmbh

The Secretary of State for Health

National Institute for Biological Standards and Control

Health Protection Agency

Stephen Poole

Mehul Ramjibhai Patel

Gerhard Dickneite

J&uuml;rgen R&ouml;misch

Harald Stauss

Peter Gronski

Bernhard Vohwinkel

Pauline Sxouter

Elaine Gray

Adrian F Bristow

Sergio H Ferreira

An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.

Monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products

A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Pharmaceutical preparation for the treatment of inflammatory processes

The invention concerns an improved pyrogenicity test for use in automated immunoassay systems, in which a sample is incubated with a monocyte-containing reagent in a pyrogen-free assay system preferably comprising a surface coated with pyrogen-free anti-cytokine antibodies. The invention also concerns pyrogen-free assay systems coated with pyrogen-free antibodies for use in these tests. The invention also relates to a test to measure the basal production of endogenous mediators of the inflammatory response by leukocytes and a method of measuring the capacity of a leukocyte to respond to a stimuli.

Pyrogenicity test for use with automated immunoassay systems

Peptides, the C-terminal amides thereof and the pharmaceutically acceptable salts of the said peptides and amides are useful in the prevention and treatment of pain.

Peptides

Peptides and pharmaceutical composition thereof in the treatment of pain

Growing community of inventors

London, United Kingdom

Stephen Poole